Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia
MONTREAL, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or "the Company") announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor developed by Eisai, for the treatment of radioiodine refractory differentiated thyroid cancer (RR-DTC) and unresectable hepatocellular carcinoma (u-HCC).
Lenvima® (lenvatinib) demonstrated a statistically significant progression-free survival prolongation and response rate in patients with progressive, differentiated thyroid cancer who had become refractory to radioactive iodine therapy1. In a separate study in patients with previously untreated unresectable HCC2, Lenvima® (lenvatinib) was proven to be non inferior to sorafenib for overall survival. In addition, Lenvima® (lenvatinib) was statistically significantly superior to sorafenib for progression-free survival and objective response rate. In 2020, there were approximately 5,3043 new patients with thyroid cancer and 2,2893 new patients with liver cancer in Colombia.
"We're pleased to announce the approval of Lenvima® (lenvatinib) in Colombia as it provides a new treatment option for radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma," said Samira Sakhia, President & Chief Executive Officer. "We look forward to working with payors to ensure access to the product for all patients who can benefit from Lenvima® (lenvatinib)."
Knight has an exclusive license from Eisai to commercialize Lenvima® (lenvatinib), Halaven® (eribulin mesylate), Fycompa® (perampanel) and Inovelon® (rufinamide) throughout Latin America, with the exception of Mexico where Eisai retains the rights to Halaven® (eribulin mesylate) and Lenvima® (lenvatinib).
About LENVIMA® (lenvatinib); available as 10mg and 4mg capsules
LENVIMA® (lenvatinib), discovered and developed by Eisai, is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA® (lenvatinib) inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
Currently, LENVIMA® (lenvatinib) has been approved for monotherapy as a treatment for thyroid cancer in over 75 countries including Japan, in Europe, China and in Asia, and in the United States for locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer. In addition, LENVIMA®(lenvatinib) has been approved for monotherapy as a treatment for unresectable hepatocellular carcinoma in over 70 countries including Japan, in Europe, China and in Asia, and in the United States for first-line unresectable hepatocellular carcinoma. LENVIMA® (lenvatinib) has been approved for monotherapy as a treatment for unresectable thymic carcinoma in Japan. It has also been approved in combination with everolimus as a treatment for renal cell carcinoma following prior antiangiogenic therapy in over 60 countries, including in Europe and Asia, and in the United States the treatment of adult patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. In Europe, the agent was launched under the brand name Kisplyx® for renal cell carcinoma. LENVIMA® (lenvatinib) has been approved in combination with KEYTRUDA® (generic name: pembrolizumab), for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) in the United States. LENVIMA® (lenvatinib) has been approved in combination with KEYTRUDA® (generic name: pembrolizumab) as a treatment for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation in the United States, and has been approved for the similar indication (including conditional approval) in over 10 countries such as Canada and Australia. In some regions, continued approval for this indication is contingent upon verification and description of clinical benefit in the confirmatory trials.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
Schlumberger M, Tahara M, Wirth LJ et al. Lenvatinib versus Placebo in Radioiodine Refractory Thyroid Cancer. N Engl J Med 2015;372(7):621-30.
Kudo M, Finn RS, Qin S, et al. Lenvatinib vs sorafenib in first-line treatment of patient with unresectable hepatocellular carcinoma: a randomised, phase 3 non-inferiority trial. Lancet 2018. Doi: 10.1016/S0140-6736(18)30207-1.